Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

Aldeyra Therapeutics, Inc.

ALDX · Nasdaq · CIK 0001341235 · Healthcare · Biotechnology

INSIDER SIGNAL

44.8 / 100

1 buyers · 1 purchase transaction lines · $417.5K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeModerate
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+13.8 / 25
Role+13.0 / 20
Recency+1.0 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: President and CEO (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Brady Todd C · $417.5K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-06-03–2026-06-03

Roles in the peak window: President and CEO. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Brady Todd CPresident and CEO
●
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

44.8 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 45.0
  2. 44.9
  3. 44.8
  4. 44.8
  5. 44.8

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

3Purchases
0Sales
0Other Form 4 lines
3SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-37.3%
3M
-52.5%
6M
-48.5%
12M
-83.7%

Volatility & liquidity

Volatility
112.5%
Beta
—
Avg daily value
USD 1.1M

Valuation

Market cap
USD 55.3M
P/E
—

Fundamentals

Profit margin
—
ROE
-76.5%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-04 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
3,470,527
Previous report
3,604,007
Avg daily volume
1,149,748
Days to cover
3.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-03Brady Todd CPurchase (P)Common Stock250,000USD 1.67USD 417,500SEC filing ↗
2026-03-19DOUGLAS RICHARDPurchase (P)Common Stock70,000USD 1.40USD 98,000SEC filing ↗
2026-03-18Alfieri MichaelPurchase (P)Common Stock5,000USD 1.42USD 7,100SEC filing ↗
2025-08-13Alfieri MichaelPurchase (P)Common Stock2,500USD 5.30USD 13,250SEC filing ↗
2024-04-05EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock37,712USD 4.74USD 178,755SEC filing ↗
2024-04-04EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock140,281USD 4.67USD 655,112SEC filing ↗
2024-04-03EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock309,847USD 4.09USD 1,267,274SEC filing ↗
2024-04-02EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock186,051USD 3.44USD 640,015SEC filing ↗
2024-04-01EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock8,374USD 3.25USD 27,216SEC filing ↗
2023-04-12Miller-Rich NancyPurchase (P)Common Stock509USD 10.13USD 5,156SEC filing ↗
2022-08-10EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock15,000USD 7.85USD 117,750SEC filing ↗
2022-08-09EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock100,000USD 7.50USD 750,000SEC filing ↗
2022-08-08EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock97,000USD 7.24USD 702,280SEC filing ↗
2022-08-05EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock141,000USD 6.95USD 979,950SEC filing ↗
2022-08-04EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock95,100USD 6.17USD 586,767SEC filing ↗

Form 4 evidence

3 transaction lines in the latest 365-day window; 63 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-03Brady Todd CPurchase (P)Common Stock250,000USD 1.67USD 417,500SEC filing ↗
2026-03-19DOUGLAS RICHARDPurchase (P)Common Stock70,000USD 1.40USD 98,000SEC filing ↗
2026-03-18Alfieri MichaelPurchase (P)Common Stock5,000USD 1.42USD 7,100SEC filing ↗
Show recent Form 4 evidence (3 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-03Brady Todd CPurchase (P)Common Stock250,000USD 1.67USD 417,500SEC filing ↗
2026-03-19DOUGLAS RICHARDPurchase (P)Common Stock70,000USD 1.40USD 98,000SEC filing ↗
2026-03-18Alfieri MichaelPurchase (P)Common Stock5,000USD 1.42USD 7,100SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerALDX
CIK0001341235
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history63 transaction lines from 2020-03-02 to 2026-06-03
31 P purchase lines · 13 S sale lines · 19 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.